Although we feel DFS was not the optimal primary end point for adjuvant therapy with an EGFR TKI even at the time the trial was conceived, OS became increasingly important once osimertinib became the preferred standard of care for patients with relapsed/metastatic EGFRm+ NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.